|Bid||5,050.00 x 6100|
|Ask||5,290.00 x 13000|
|Day's Range||5,120.00 - 5,172.00|
|52 Week Range||3,996.00 - 5,520.00|
|PE Ratio (TTM)||19.30|
|Dividend & Yield||2.80 (4.24%)|
|1y Target Est||N/A|
When Emma Walmsley addressed GSK's 100,000-strong global workforce for the first time this year, employees gathered to hear the new chief executive explain her strategy noticed a striking contrast with ...
IBD's 439-company Biotech industry group is now ranked fourth out of 197. How far can the rally go?
GlaxoSmithKline's new chief executive, who has already made her mark with plans to divest some nutritional products, will turn next week to the main business of focusing the company's pipeline of new drugs. Despite her non-pharmaceutical background in consumer brands, Emma Walmsley sees improving drug research productivity as her top priority, and she wants Britain's biggest drugmaker to have fewer but potentially more lucrative new medicine launches in future.